Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13407)	1/16/1998 12:21:00 PM
From: celeryroot.com	Respond to of 32384

looks like a continuation of yesterday

To: Henry Niman who wrote (13407)	1/16/1998 6:06:00 PM
From: medsunman	Read Replies (2) \| Respond to of 32384

Henry, I've been pretty busy this week, so I haven't had a chance to respond to questions on this thread. I'll try to add more info next week based on my impressions from H&Q. However, in response to your question, LGND was only mentioned in passing at the wrap-up session. Rich van den Broek chose Gilead as his top pick. (BTW, Meg Malloy chose ERGO as one of her top three - so go figure.) Without getting into specifics, I got the impression that many viewed LGND as fully valued at these prices given that its near-term market opportunities (KS & CTCL) are so small. With positive EPS projected in '99, investors within a quarter or so are going to start looking at projected '99 EPS, and stock values are going to reflect those EPS expectations. In the case of LGND, EPS numbers are small (especially if you net out from operating profit all the non-recurring milestone revenue). It was my impression that the big revenues and earnings from expanded off-label cancer sales, diabetes, ostoporosis, oral EPO, etc... are being heavily discounted, and essentially not counted. IMO, many investors aren't recognizing much potential beyond these small indications (KS and CTCL). I could be wrong, but that's the impression I got.